Literature DB >> 12047389

Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin.

Danny M Hatters1, Mark R Wilson, Simon B Easterbrook-Smith, Geoffrey J Howlett.   

Abstract

The effect of the extracellular chaperone, clusterin, on amyloid fibril formation by lipid-free human apolipoprotein C-II (apoC-II) was investigated. Sub-stoichiometric levels of clusterin, derived from either plasma or semen, potently inhibit amyloid formation by apoC-II. Inhibition is dependent on apoC-II concentration, with more effective inhibition by clusterin observed at lower concentrations of apoC-II. The average sedimentation coefficient of apoC-II fibrils formed from apoC-II (0.3 mg.mL-1) is reduced by coincubation with clusterin (10 microg x mL(-1)). In contrast, addition of clusterin (0.1 mg x mL(-1)) to preformed apoC-II amyloid fibrils (0.3 mg x mL(-1)) does not affect the size distribution after 2 days. This sedimentation velocity data suggests that clusterin inhibits fibril growth but does not promote fibril dissociation. Electron micrographs indicate similar morphologies for amyloid fibrils formed in the presence or absence of clusterin. The substoichiometric nature of the inhibition suggests that clusterin interacts with transient amyloid nuclei leading to dissociation of the monomeric subunits. We propose a general role for clusterin in suppressing the growth of extracellular amyloid.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047389     DOI: 10.1046/j.1432-1033.2002.02957.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

1.  An equilibrium model for linear and closed-loop amyloid fibril formation.

Authors:  Shuo Yang; Michael D W Griffin; Katrina J Binger; Peter Schuck; Geoffrey J Howlett
Journal:  J Mol Biol       Date:  2012-02-24       Impact factor: 5.469

2.  Identification of human plasma proteins as major clients for the extracellular chaperone clusterin.

Authors:  Amy R Wyatt; Mark R Wilson
Journal:  J Biol Chem       Date:  2009-12-07       Impact factor: 5.157

Review 3.  Apolipoproteins and amyloid fibril formation in atherosclerosis.

Authors:  Chai Lean Teoh; Michael D W Griffin; Geoffrey J Howlett
Journal:  Protein Cell       Date:  2011-03-12       Impact factor: 14.870

4.  Isotopic N,N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease.

Authors:  Yuan Liu; Hua Zhang; Xiaofang Zhong; Zihui Li; Henrik Zetterberg; Lingjun Li
Journal:  J Proteomics       Date:  2022-02-03       Impact factor: 4.044

5.  Clusterin Binds to Aβ1-42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation.

Authors:  Marten Beeg; Matteo Stravalaci; Margherita Romeo; Arianna Dorotea Carrá; Alfredo Cagnotto; Alessandro Rossi; Luisa Diomede; Mario Salmona; Marco Gobbi
Journal:  J Biol Chem       Date:  2016-02-16       Impact factor: 5.157

6.  Proteomic analysis of human frontal and temporal cortex using iTRAQ-based 2D LC-MS/MS.

Authors:  Long Xu; Haidan Sun; Yang Zhang; Zhengguang Guo; Xiaoping Xiao; Xin Zhou; Kun Hu; Wei Sun; Bo Wang; Weiming Liu
Journal:  Chin Neurosurg J       Date:  2021-05-05

Review 7.  Systemic amyloidosis: lessons from β2-microglobulin.

Authors:  Monica Stoppini; Vittorio Bellotti
Journal:  J Biol Chem       Date:  2015-03-06       Impact factor: 5.157

8.  Plasma protein characteristics of long-term hemodialysis survivors.

Authors:  Yao-Ping Lin; Chih-Yu Yang; Chen-Chung Liao; Wen-Chung Yu; Chin-Wen Chi; Chao-Hsiung Lin
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

9.  Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan.

Authors:  Agueda Rostagno; Miguel Calero; Janice L Holton; Tamas Revesz; Tammaryn Lashley; Jorge Ghiso
Journal:  Neurobiol Dis       Date:  2021-07-21       Impact factor: 7.046

10.  Expression and purification of chaperone-active recombinant clusterin.

Authors:  Rebecca A Dabbs; Mark R Wilson
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.